60
Participants
Start Date
April 9, 2014
Primary Completion Date
May 10, 2017
Study Completion Date
May 10, 2017
PF-06647263
Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
PF-06647263
Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
Sarah Cannon Research Institute, Nashville
Tennessee Oncology, PLLC, Nashville
Karmanos Cancer Institute, Detroit
The University of Texas MD Anderson Cancer Center, Houston
Huntsman Cancer Hospital / University of Utah, Salt Lake City
Huntsman Cancer Institute-University of Utah, Salt Lake City
Comprehensive Cancer Centers Of Nevada, Las Vegas
Massachusetts General Hospital, Boston
Brigham & Women's Hospital (BWH), Boston
Dana-Farber Cancer Institute (DFCI), Boston
Lead Sponsor
Pfizer
INDUSTRY